Medical technology Sonova confirms annual targets after first half-year
Sonova grew in the first half of 2025/26. With the figures presented on Friday, the Group believes it is well on track to meet its confirmed targets. Meanwhile, the Group is planning changes for the Hearing Instruments and Audiological Care divisions.
14.11.2025, 07:22
SDA
These are the first figures presented jointly by the new duo Eric Bernard (CEO) and Elodie Carr-Cingari (CFO). According to the figures, sales in local currencies rose by 4.9 percent to 1.82 billion Swiss francs in the first six months of 2025/26 (as at the end of September). According to Sonova, however, exchange rates reduced growth. In Swiss francs, the figure for the period was down 1.0 percent.
The company from Stäfa in Zurich, known for its Phonak brand, reported normalized operating profit (EBITA) of 316.1 million (+16% in LC). The corresponding margin rose to 17.4 percent (previous year: 17.0%).
The bottom line was a net profit of CHF 192.3 million (previous year: CHF 211.7 million). Sonova's performance fell short of analysts' expectations (AWP consensus), particularly at the profit level.
Outlook confirmed
"Despite persistently volatile markets, whose growth is developing below the historical level as expected", Sonova confirms its previous targets for the full year 2025/26. This outlook is based on the assumption that no significant additional tariffs are imposed and no major economic turbulence occurs beyond that already known at the time of publication of this report.
Specifically, the company is aiming for consolidated sales growth of 5 to 9 percent and normalized EBITA (adjusted for special effects but including restructuring costs) of 14 to 18 percent. On the exchange rate side, Sonova expects a negative impact of 6 percentage points on reported sales growth in Swiss francs and 13 to 14 percentage points on the increase in normalized EBITA for the financial year.
